Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantLoading investors…
Activity from announced rounds
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.